Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Ann Arbor, Michigan 48103


The purpose of this study is to find out whether Varivax is safe for use in children with kidney transplants and whether it protects children from serious infection. Varivax is a vaccine against varicella zoster virus (VZV), the virus that causes chickenpox (varicella) and shingles (zoster). Healthy children are already receiving Varivax shots to protect them from chickenpox. Few children with kidney transplants have received Varivax because doctors have been concerned that Varivax might cause serious reactions in them. On the other hand, VZV infection can be a life-threatening disease in these children. For this reason, doctors ultimately want to learn whether Varivax might safely prevent VZV infections in children who have had kidney transplants.

Study summary:

Pediatric renal transplant patients face a lifetime of immunosuppressive therapy that place them at high risk for potentially life-threatening infection by primary varicella zoster virus (VZV). Treatment for acute episodes of VZV infection is possible but expensive and provides no long-term protection. Furthermore, therapy to overcome VZV infections can lead to renal graft rejection. Varivax has proven safe, immunogenic, and effective in the normal host and has been recommended for universal administration in the general population at age 12 months. It is not currently labeled for use in immunocompromised patients. However, recent studies in pediatric leukemia and pediatric renal transplant patients suggest that attenuated live vaccine can confer protection with minimal adverse events even in the presence of immunosuppression, providing encouragement for more careful studies of VZV immunization in renal transplant patients. This study aims to quantify the safety and immunogenicity of Varivax in the population of pediatric renal transplant patients least susceptible to VZV infection, i.e., those on minimal maintenance immunosuppression and at least 1 year out from transplant. Patient enrollment is staged to allow study physicians to closely monitor patients for signs of disseminated varicella reactions or graft rejection. Initially only 1 patient will be enrolled in the study. If the first patient reaches Week 8 without a severe adverse reaction, 3 study centers will then enroll 3 additional patients. If 8 weeks later these 3 patients have had no severe adverse reactions, the same 3 study centers will enroll 3 more patients. At the end of this period, having ascertained the safety of the vaccine in the first 7 patients, the study will be opened to the remaining centers. Patients receive 2 doses of Varivax 6 to 8 weeks apart. Each week for 6 to 8 weeks after the first vaccine dose, the patient undergoes venipuncture and clinical assessment to characterize renal graft and liver function and identify any signs of varicella infection. Additional telephone follow-up occurs on Day 4 and twice weekly thereafter. Parents or guardians monitor the patient for evidence of rash or fever and immediately report any rashes or fevers to study physicians. If, after 6 to 8 weeks, the patient demonstrates no severe reactions to the vaccine and requires no antiviral therapy, the patient receives the second vaccine dose. The patient again receives weekly on-site and telephone follow-up for 6 weeks. Other visits occur 9 weeks and 14 weeks after the second vaccine dose and 1 year after the first vaccine dose. At these visits the patient undergoes venipuncture and clinical assessment to identify potential rejection events or varicella infection and to characterize VZV antibody responses and cytokine changes in response to the vaccine.


Inclusion Criteria: Your child may be eligible for this trial if he/she: - Had a kidney transplant 1 year ago or more; - Is between 2 and 21 years of age (parent or guardian's signed informed consent required if under 18); - Is taking stable, maintenance doses of immunosuppressive drugs for his/her kidney transplant; and - Is generally in good health. Exclusion Criteria: Your child will not be eligible for this trial if he/she: - Has had any rejection episodes in the last 6 months or has other problems with their kidneys; - Was in the hospital for a major infection in the last 30 days; - Has a history of VZV infection, including chicken pox or shingles; - Has ever received a VZV vaccine, including Varivax®; - Lives with a person whose immune system does not work well; - Is allergic to certain medications; - Is unable to return for the prescribed follow-up check-ups; - Has no phone or pager; or - Has had blood or plasma transfusions or taken certain drugs in the last 6 months.

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients

Official Title:

Evaluation of the Safety and Immunogenicity of Varivax® (Live-Attenuated Varicella-Zoster Virus Vaccine) in Pediatric Renal Transplant Recipients

Overall Status:


Study Phase:

Phase 1



Minimum Age:

2 Years

Maximum Age:

21 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Institute of Allergy and Infectious Diseases (NIAID)

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Slow enrollment

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Amir Tejani, MD
Study Chair
North American Pediatric Renal Transplantation Study (NAPRTCS)

Study Dates

Start Date:February 1998
Completion Date:June 16, 2001
Completion Type:Actual
Primary Completion Date:June 16, 2001
Primary Completion Type:Actual
Verification Date:February 2017
Last Changed Date:February 14, 2017
First Received Date:March 28, 2000

Study Outcomes

Outcome Type:Primary Outcome
Measure:Rejection events
Time Frame:1 year
Safety Issues:False
Description:Increase in creatinine Renal biopsy
Outcome Type:Primary Outcome
Measure:Varicella related adverse reactions
Time Frame:1 year
Safety Issues:False
Description:Fever and local (<1 inch from inoculation site) lesions Fever and lesions outside the 1 inch inoculation site Lesions outside the 1 inch inoculation site Clinical signs of pneumonitis Clinical or chemical signs of hepatitis Development of thromboc
Outcome Type:Primary Outcome
Measure:Immediate adverse reactions
Time Frame:30 minutes post vaccination
Safety Issues:False

Study Interventions

Intervention Type:Biological
Description:Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
Arm Name:Varivax®
Other Name:live-attenuated varicella zoster virus vaccine

Study Arms

Study Arm Type:Experimental
Arm Name:Varivax®
Description:0.5 mL of Varivax administered subcutaneously in the right upper arm (deltoid region).

Study Agencies

Agency Class:NIH
Agency Type:Lead Sponsor
Agency Name:National Institute of Allergy and Infectious Diseases (NIAID)
Agency Class:Industry
Agency Type:Collaborator
Agency Name:Merck Sharp & Dohme Corp.

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.